KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Average (2016 - 2025)

Historic Equity Average for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to $6.0 billion.

  • Biomarin Pharmaceutical's Equity Average rose 1293.62% to $6.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 1293.62%. This contributed to the annual value of $5.3 billion for FY2024, which is 1103.99% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Equity Average of $6.0 billion as of Q3 2025, which was up 1293.62% from $5.9 billion recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Equity Average peaked at $6.0 billion during Q3 2025, and registered a low of $4.1 billion during Q1 2021.
  • In the last 5 years, Biomarin Pharmaceutical's Equity Average had a median value of $4.7 billion in 2023 and averaged $4.9 billion.
  • Data for Biomarin Pharmaceutical's Equity Average shows a peak YoY increase of 2995.23% (in 2021) and a maximum YoY decrease of 455.79% (in 2021) over the last 5 years.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Equity Average stood at $4.3 billion in 2021, then grew by 7.5% to $4.6 billion in 2022, then grew by 7.38% to $4.9 billion in 2023, then grew by 12.42% to $5.5 billion in 2024, then grew by 9.14% to $6.0 billion in 2025.
  • Its Equity Average stands at $6.0 billion for Q3 2025, versus $5.9 billion for Q2 2025 and $5.7 billion for Q1 2025.